CD86 and cancer: In the current study, we have observed a shift from a Th2 to Th1 effector phenotype, an increase in the frequency of CD8+ T cells, an increase in CD8+ effector memory cells, an increase in CD86+ DCs, an increase in m-MDSCs with a decrease of g-MDSCs, and an increase in cancer cell-killing M1 macrophages.